

Office Note

Sub : Minutes of 1st meeting of Technical Committee (2018-19) for assessment of application of under change in product-mix held on 21/4/2018 at 11.00 a.m. at Kalpataru Point, 3rd Floor, Sion

Ref: : 1. Amendment to EIA notification no. S.O. 3518(E) dated 23rd November 2016
2. Office Memorandum dated 16/6/2017
3. Technical Committee meeting dated 21/4/2018

Submitted,

The Technical Committee meeting for assessment of application of under change in product-mix of the Board was held on 21/4/2018. Two agenda items were placed before the meeting and cases were presented by the unit. Accordingly, a minutes of the meeting prepared and same is placed for approval, please.

R. Injulkar
21/4/18

R.K. Injulkar

Field Officer, AS(T) Section

Regional Officer (HQ):

Minutes of meeting is submitted for approval please.

[Signature]
21/04/18

~~AS(T)~~

MOM approved

Submitted for kind perusal M.

Reed. on
4/5/18
M.S.

[Signature]
8/5/18

[Signature]
21/5/18

FO (RD)

for kind perusal M.

[Signature]

MAHARASHTRA POLLUTION CONTROL BOARD



Minutes of 1st meeting of Technical Committee (2018-19) for assessment of application of under change in product-mix held on 21/4/2018 at 11.30 a.m. at Kalpataru Point, 3rd Floor, Sion.

The Technical Committee meeting for assessment of application of under change in product-mix of the Board was held on 21/4/2018. The following members of the Technical Committee were present for the meeting:

- | | |
|--|-----------------|
| 1. Shri P.K.Mirashe, Assistant Secretary (Tech), MPCB | Chairman |
| 2. Dr B.R.Naidu, Zonal Officer, CPCB, Vadodara | Member |
| 3. Shri A. M. Pimpalkar, Scientist -1, Environment Dept, GoM | Member |
| 4. Dr. Tuhin Banerjee, Scientist Fellow, NEERI, Mumbai | Member |
| 5. Shri Anurag Garg, Associate Prof. IIT, Mumbai | Member |
| 6. Shri N.N.Gurav, Regional Officer, HQ, MPCB | Member convener |


Dr. Prakash P. Wadgaonkar, Chief Scientist, NCL, Pune could not attend the meeting. Leave of absence was granted to them.

The Chairman of the Committee welcomed the Committee members and the minutes of the 4th meeting of the Technical Committee (2017-18) were confirmed. Two agenda items were placed before the meeting. Committee deliberated on the agenda items and following decisions were taken.

Sr. No.	Name of Industry	Recommendations
1	M/s Hikal Ltd. Plot No. T-21, MIDC Taloja, Dist-Raigad	PP gave presentation on amendment in existing consent for change in product-mix. After interaction with the PP, it was noted 1. PP was unable to show the proper mass balance of the existing as well as proposed products. 2. PP Shows only hydraulic load of the existing as well as proposed products, however, unable to show the Organic Load. 3. Also NIPL certificate did not have any supporting calculations of each product i.e. existing as well as proposed products. Finally, after due deliberations, it was decided to defer the case and was advised the PP to furnish information i.e. Detailed chemical reactions, mass balance, product wise pollution load alongwith unit-wise BOD- COD reduction and details of product mix carried out from EC granted.

Sr. No.	Name of Industry	Recommendations
		<p>) AZTH3 Intermediate (3 MT/M), 2-Mercapto-N-methylbenzamide (3MT/M), Anticancer Fragment A (1.5 MT/M), Anticancer Fragment B (1 MT/M), Anticancer Fragment C (1 MT/M), Ethyl 2,4-dihydroxy-6-pentylbenzoate (Ethyl Olivetolate) (2 MT/M), (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol (Menthadienol) (2MT/M), Citarabine intermediate (5 MT/M), 1,2-Di-P-tolyethane-1,2-dione dioxime (3 MT/M), Ethyl 2,4,6-tri-O-benzoyl-β-D-thiogalactopyranoside (PF-06460245) (3 MT/M), Amine HCl Salt 090602 (3 MT/M), N-(3,5-dichloro-4-((6-oxo-1,6-dihydropyridazin-3-yl) oxy) phenyl) benzamide (Intermediate-C) (2 MT/M), N-cyanoacetylurethane (NCAU) (2 MT/M), (R)-2-(2-(3-(((benzyloxy)carbonyl) amino)propyl)phenoxy)propyl 4-methylbenzenesulfonate (LP101-9c) (1 MT/M), Adrenalone HCL (5 MT/M), Dibenzyl Artreone (5 MT/M), 2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo[d]imidazol-1-yl) quinolin-8-ol (ASP-187) (3MT/M)</p> <p>5. Overall total production quantity will be 65 MT/M (Existing- 65 MT/M)</p> <p>6. TDS & COD load will be 1171 Kg/day & 1112 Kg/day (Existing load TDS- 1176 Kg/day & COD- 1186 Kg/day)</p> <p>7. Process Emission will be 441.64 Kg/day (Existing-577.34 Kg/day)</p> <p>8. Organic Residue will be 914 Kg/day (Existing-920 Kg/day)</p> <p>9. Inorganic + Residual Salt will be 1360 Kg/day (Existing-1376 Kg/day)</p> <p>10. Spent Carbon will be 332 Kg/day (Existing- 333.3 Kg/day)</p> <p>There is no increase in pollution load i.e effluent quantity, air emissions and hazardous waste.</p> <p>In the view of above, it was decided to recommend the case for change in product-mix and submit all the documents presented during presentation to Board office.</p>

The meeting ended with vote of thanks to Chair.


(N.N.Gurav)
Regional Officer (HQ)
Member convener


(P.K. Mirashe)
Asst. Secretary (Tech)
Chairman

Sr. No.	Name of Industry	Recommendations
2	Amri India Ltd. Plot No. G-1/1, 1/2, MIDC Waluj, Aurangabad-431136	<p>Committee noted that, industry has submitted the information/proposal for change in product-mix. The PP has given the presentation on material balance, water budgeting and pollution aspects due to proposed change in product-mix.</p> <p>After due deliberation, it was noted that proposal is for</p> <ol style="list-style-type: none"> <li data-bbox="1155 381 2499 600">1. Reduction of production quantity of Atenolol (7.5 MT/M to 6 MT/M), Diatrizoate Sodium (7.5 MT/M to 6 MT/M), Diatrizoate Meglumine (9 MT/M to 6 MT/M), Metformin Hydrochloride (10 MT/M to 5 MT/M), 4-Bromo-2-fluro -N-methyl benzamide (MDV2) (11 MT/M to 8 MT/M), 4-Amino pyrazolopyrimidine [ML739] (9 MT/M to 6 MT/M), 2-Acetate (9 MT/M to 6 MT/M) and N,N-bis(2.4-dichlorobenzyl) hydroxylamine (Compound 1534 Water villie) (10 MT/M to 6.5 MT/M). <li data-bbox="1155 633 2499 1502">2. Retained Products: Production quantity of Furosemide (15 MT/M), Isosorbide-5-mononitrate (6 MT/M), Dilute Isosorbide-5-mononitrate (10 % to 90%) (10 MT/M), 4-isothiocyano-2-(trifluoromethyl) benzonitrile (MDV3100-6) [MDV -6] (4.5 MT/M), Cinnarizine (1 MT/M), (1-((2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4yl)methyl)-2-butyl-4chloro - 1H-imidazol-5-yl)methanol [Losartan] (2 MT/M), Fluconazole (1 MT/M), Propranolol Hydrochloride (2 MT/M), Venlafaxine Hydrochloride (2 MT/M), 7-acetyl-1,2,4,6,7,8,12,13,14,15,16,17-dodecahydrospiro [cyclopenta[a]phenanthrene-3,2'-[1,3]dioxolan]-17-yl acetate (ketal acetate) (3 MT/M), (R)-2,7,8-trimethyl-2-((4R,8R)-4,8,12-trimethyltridecyl) chroman-6-01 or D-α-Tocopheryl polyethylene glycol Succinate Vitamin-E TPGS (3 MT/M), 2-3((3-Fluoro-4-(methylcarbamoyl) phenyl) amino)-2-methylpropanoic acid (MDV4) (6 MT/M), 5-Bromo-2-(2-methyl-2H-tetrazol-5-yl)pyridine (DA-3) (3 MT/M), 6-Chloro 3 methyl Uracil (CMU) (2.5 MT/M), 1-Benzyl-4-Phenylpiperidine-4-caarbonitrile Hydrochloride (Nitrile Chloride) (6.5 MT/M), Acetyl Benzyl Amine (15 MT/M), Sodium benzofuran-6-carboxylate (Synthon A) (4 MT/M), 2-(tert-Butoxycarbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid (Synthon B) (4 MT/M), Benzyl 2-amino-3-(3-(methylsulfonyl) phenyl) propanoate Hydrochloride (Synthon C) (4 MT/M), S-methyl 2-methylpyrrolidine-2-carboxylate Neuren-4 (3 MT/M), (S)-dibenzyl 2-((S)-1-(2-(benzyloxy) carbonyl) amino) acetyl)-2-methylpyrrolidine-2-carboxamido) pentanedioate Neuren-7 (3 MT/M), Propionyl Chloride (15 MT/M), 2-Amino-5-bromo Benzoxazole [ML 737] OR tert-butyl (5-bromobenzo[d]oxazol-2-yl)carbamate or (BOC-ML737) (4 MT/ M), Bromofluoro methane (BFM) (0.5 MT/M), Benzyl 2-bromo ethyl ether (BBEE) (0.75 MT/M), 1,6-Di Bromo hexane (5.4 MT/M), 5-bromo-3-methyl-6-oxo-1,6-dihydropyridine-2-carboxamide (Methyl analogue of pyridine der) (eFT000776) OR N-(6-aminopyrimidin-4-yl) cyclopropanecarboxamide (eFT000775) (1 MT/M), 1-(benzyloxy)-4-bromo-2,5-dimethoxybenzene Compound 4 (SGL chemistry) (2 MT/M), 4-acetyl-4'-(benzyloxy)-2',5'-

Sr. No.	Name of Industry	Recommendations
		<p>dimethoxy-[1,1'-biphenyl]- 2-carboxylic acid Compound 7 (SGL chemistry) (2 MT/M), tert - butyl((1s,4s)-4-aminocyclohexyl)carbamate [BOC - CIS -Diamine] (3 MT/M), 2-(4-(benzyloxy)-3-nitrophenyl)oxirane [Borregaard NSO] (3 MT/M), 6-((2-(3,4- dihydroxyphenyl)-4-oxo-4H-chromen-3-yl)oxy)-6-oxohexanoic acid [NP-202] (3 MT/M), Miconazole Nitrate (1 MT/M), Timolol Maleate (Timolol) (1 MT/M), Warfarin Sodium Clathrate (Warfarin) (1 MT/M), Dilute Caustic Lye (Byproduct) (10 MT/M), and Distillation of Spent Solvent (20 MT/M) remains unchanged.</p> <p>3. Removal of Pyridine -2-Aldoxime (6 MT/M), Tyloxapol (4 MT/M), Domperidone (4 MT/M), 3-([1,1'-biphenyl]-4-yl)-3,4-dihydronaphthalen- 1(2H)-one Difenacoum Stage-5 (3 MT/M), 3-([1,1'-biphenyl]-4-yl)-3, 4-dihydronaphthalen-1(2H)-ol Difenacoum Stage-6 (3 MT/ M), 5-Bromo-2-chloro-1,3-dimethoxybenzene (OMS-2) (4 MT/M), (5-Methyl-1,3,4-thiadiazol-2-yl)bromide (OMS-6) (4 MT/M), 4-(5-Methyl-1,3,4-thiadiazol-2-yl) benzaldehyde (OMS 7) (6.5 MT/M), ethyl 7-iodo-2,2-dimethylheptanoate (ETC - 1002 Esperion) (10.5 MT/M), (S)-7a-methyl-2,3,7,7a-tetrahydro-1H-indene-1,5(6H)-dione K00006 (Hikal/WuXi) (6 MT/M), 4-methoxyindolin-2-one Elanco (Compound-5) (3 MT/M), (4R,4aS,7S,12bS)-7-(2,5,8,11,14,17,20-heptaaxadocosan-22-yloxy)-3-(cyclopropylmethyl)-2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzofuro [3,2-e]isoquinoline-4a,9-diyl diacetate Naloxgol-3[Naloxgol-3 (stage 1 &2)] (3 MT/M), (3aR,4R,7aS)-methyl 4-((S)-hydroxy((R)-2-oxo-1,3-dioxolan-4-yl)methyl)-2-methyl-4,7a-dihydro-3aH-pyrano[3,4-d]oxazole-6-carboxylate [CS 8958 (Biota-PP)] (2 MT/M), D-Alanine Isopropyl Ester HCL – 2 (2 MT/M), Palmitoleic Acid Ethyl Ester Concentrates (4.5 MT/M), 2-(3-oxobutanamido)benzoic acid [FT 11-1 Starting Material] (3 MT/M), 2,4-dichloro 1,3,5 triazine (Bayer) (2 MT/M), Ethyl 8-chloro-6-(trifluoromethyl) imidazo [1,2-a]pyridine-2-carboxylate [IN-96480 (Dupont)] (2 MT/M), CBz-tert-leucine MIPA salt (14 MT/M), 2-amino 2-thioxoethyl carbamate (2 MT/M), Poly peptide BHA-DBL8 (1 MT/M), N-Acetyl leucine (Mylan) (2 MT/M), Thieno[3,4-c]furan-1,3(4H,6H)-dione (Compound 13 Verrica) (1 MT/M), 2-Cyclopenta-2,4-dienyl-7-(4,4,5,5-tetramethyl-[1,3,2]-dioxaborolan-2-yl) quinolone (1 MT/M), and 3-(4-Bromo-5-chloro-4aH-pyrido[1,2-c] pyrimidin-1-yl) cyclobutanone (1 MT/M)</p> <p>4. Addition of 25 nos. of new products - Anecortave (5HC) OR Hydrocortisone Base (HC) OR Tetraene Acetate (2TR) (3MT/M), Solifenacin Succinate (2 MT/M), Fesoterodine (1MT/M), Deferasirox (2MT/M), Fluticasone furoate (2MT/M), Indacaterol (2MT/M), 2-(4-Chloro-3-(chlorosulfonyl)benzoyl)benzoic acid (Chlorthalidone Intermediate-1 OR BBA) /intermediates (15 MT/M), (4S-trans)-4-(N-acetyl-N-ethylamino)-5,6-dihydro-6-methyl-4H-thien-(2,3-b)-thiopyran-7,7-dioxide (Chiral Acetamide (5 MT/M), (2-Formamido-1.3-thiazol-4-yl) glyoxylic acid</p>

Saurin

gaurin